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Conclusion: Effectiveness of therapy can be better determined by PET-imaging measurements of genomic biomarkers targeted specifically,
than by PET imaging of metabolic activity of a tumor. Cu-64-PNA PET-imaging provides a genetic tool for evaluation of therapeutic efficacy.
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Materials and Method: Peptide Nucleic Acid (PNA) that
would hybridize with HER2 mRNA was synthesized together
with D (CSKC), a cyclic peptide, that facilitated internalization
of the PNA via IGFR expressed on breast (BC) cancer cells
and DOTA that chelated Cu-64. Mice (n=8) with BT474
ER+/HER2+ human BC received doxorubicin (DOX), 1.5
mg/kg) intraperitoneally, three times a week. Mice (n=3)
without DOX treatment served as controls. All mice were
PET imaged with F-18-FDG and 24-48 hrs later with Cu-64-
PNA. PET imaging was performed before and 72 hrs after
each treatment. Standard Uptake Values (SUV) for tumors
were determined and % change calculated. Animal body
weight (BW) and tumor volume (TV) were measured.
Results: Following each of the three DOX
treatments, tumor SUV for Cu-64-PNA declined
to 54±17%, 41±15%, 29±7% of pretreatment
SUV (P<0.05), as compared to
42±22%,31±18%, 13±9% (P<0.05), SUVs
respectively for F-18-FDG. In control mice the
corresponding % SUVs for Cu-64-PNA were
145±82% , 165 ±39 and 212±105%, and for F-
18-FDG 108±28%, 151±8 and 152±35%. In
treated mice, at the end of three DOX
treatments, BW was 101.7±12.7% while TV
declined to 35.1±35%. In control mice, BW
remained 107.8±9.3% and TV averaged
181.3±51.5%.
DETERMINING EFFICACY OF BREAST CANCER THERAPY BY PET IMAGING OF HER2
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Objective: Monitoring the effectiveness of therapy early
and accurately continues to be challenging.
We hypothesize that determination of HER2 mRNA in
malignant Breast Cancer cells by PET imaging, before
and after treatment, would reflect therapeutic efficacy.
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Cross Sectional PET Images of a BT474 Tumor
Bearing Mouse, Before and After DOX Treatment
Note: Reduced tumor volume as a result of DOX treatment.
These results can be better appreciated in figure below.
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Study
(n=8)
Pre-
Treatments Post-Treatments
1st Week 3rd Week % Change 5th Week % Change 7th Week % Change
Cu-64-PNA 0.95 0.32 0.56 0.18 54 17(P<0.05)
0.43 0.23
(P<0.05)
41 15
(P<0.05) 0.32 0.14
29 7
(P<0.05)
F-18-FDG 2.34 0.99 1 0.85 42 22 0.77 0.6 31 18 0.34 0.25 13 9
Control (n=3) Initial No Treatment (Control)
Cu-64-PNA 0.49 0.21 2.03 1.6 145 82(P<0.05) 0.81 0.7
165 39
(P<0.05) 1.04 0.12
212 105
(P<0.05)
F-18-FDG 1.9 1.12 0.56 0.18 108 28(P<0.05) 2.8 2.2
151 8
(P<0.05) 4.1 3.7
152 35
(P<0.05)
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Ratios of PET Pixel Counts in Each 1x1x1 mm Voxel Across a
Central 1 mm Slice of BT474 Tumor Before and After Three
Treatments of DOX (F-18-FDG (1 hr) and Cu-64-PNA (4 hr)
Note: Significantly reduced tumor pixel count ratios with
Cu-64-PNA than with F-18-FDG.
Arbitrary Values of a BT474 Tumor (right) and
Contralateral Normal Tissue (left), Derived from a
Surface Rendered PET/CT Image of a Mouse (4 hr
After Administration of Cu-64-PNA)
